| 申请日期 | 2025-07-13 | 申请号 | JP2018506346 |
| 公开（公告）号 | JP2018522907A | 公开（公告）日 | 2018-08-16 |
| 公开国别 | JP | 申请人省市代码 | 全国 |
| 申请人 | CELLECTIS | ||
| 简介 | Methods of developing genetically engineered immune cells for immunotherapy, which can be endowed with Chimeric Antigen Receptors targeting an antigen marker that is common to both the pathological cells and said CD38 immune by the fact that the genes encoding said markers are inactivated in said immune cells by a rare cutting endonuclease such as TALEN, Cas9 or argonaute. | ||
|
您还没有登录，请登录后查看下载地址
|
客服热线：
手机版
二维码
